无咖啡因咖啡摄入与总体及部位特异性癌症风险
这项前瞻性队列研究纳入护士健康研究(1984-2020)75 988名女性和卫生专业人员随访研究(1986-2020)45 349名男性,评估无咖啡因咖啡摄入与总体及14种部位特异性癌症风险的关系。结果显示无咖啡因咖啡摄入与总体癌症风险无关(每增加1杯/天,HR 1.00,95%CI 0.98-1.01),与结直肠癌(HR 0.96,95%CI 0.92-0.99)和侵袭性前列腺癌(HR 0.93,95%CI 0.87-0.99)风险呈负相关;男性从不吸烟者中膀胱癌风险升高,但需进一步研究。
要点
- 无咖啡因咖啡摄入与总体癌症风险无关(每增加1杯/天,HR 1.00,95%CI 0.98-1.01)。
- 与结直肠癌(HR 0.96,95%CI 0.92-0.99)和侵袭性前列腺癌(HR 0.93,95%CI 0.87-0.99)风险呈负相关。
- 男性从不吸烟者中膀胱癌风险升高,但需进一步研究。
核心结论
- 较高的无咖啡因咖啡摄入与总体癌症风险无关。
- 观察到的男性膀胱癌风险显著升高需进一步研究。
研究设计与样本
- 前瞻性队列研究,纳入护士健康研究(1984-2020)75 988名女性和卫生专业人员随访研究(1986-2020)45 349名男性。
- 基线及每4年使用经验证的食物频率问卷评估无咖啡因咖啡摄入。
- 采用Cox比例风险模型估计风险比(HR)和95%置信区间(CI),调整常规咖啡摄入和其他潜在混杂变量。
主要发现
- 随访长达36年,共记录34 120例新发癌症病例(女性22 688例,男性11 432例)。
- 无咖啡因咖啡摄入与总体癌症风险无关(每增加1杯/天,HR 1.00,95%CI 0.98-1.01)。
- 结直肠癌风险呈负相关(HR 0.96,95%CI 0.92-0.99),侵袭性前列腺癌风险呈负相关(HR 0.93,95%CI 0.87-0.99)。
- 男性从不吸烟者中,与不饮用者相比,无咖啡因咖啡摄入0.1-0.9、1-1.9、2-2.9和≥3杯/天的膀胱癌HR分别为1.30(95%CI 1.01-1.68)、1.42(95%CI 1.00-2.03)、1.43(95%CI 0.91-2.23)和1.79(95%CI 0.92-3.50),线性趋势边缘显著(Ptrend=0.06)。
- 该正关联在多种敏感性分析中保持稳健,并在8年滞后分析中变得更强;女性中未观察到无咖啡因咖啡与膀胱癌的关联(Psex-heterogeneity=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 观察到的男性膀胱癌风险显著升高需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coffee is generally considered safe regarding cancer risk. However, concerns have emerged over methylene chloride, a chemical used in decaffeination, due to its carcinogenic properties. The potential cancer risk from methylene chloride residue in decaffeinated coffee remains unclear. PATIENTS AND METHODS: This prospective cohort study included 75 988 women (Nurses' Health Study, 1984-2020) and 45 349 men (Health Professionals Follow-up Study, 1986-2020). Decaffeinated coffee consumption was assessed at baseline and every 4 years using a validated food frequency questionnaire. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of total and 14 site-specific cancers associated with decaffeinated coffee consumption, adjusted for regular coffee intake and other potential confounding variables. RESULTS: During up to 36 years of follow-up, we documented 34 120 incident cancer cases (22 688 in women and 11 432 in men). Overall, decaffeinated coffee intake was not associated with higher total cancer risk [per 1 cup/day higher intake, HR 1.00 (95% CI 0.98-1.01)]. For specific cancer type, an inverse association was observed for colorectal [HR 0.96 (95% CI 0.92-0.99)] and aggressive prostate [HR 0.93 (95% CI 0.87-0.99)] cancer. An observed higher lung cancer risk for decaffeinated coffee attenuated to null when restricted to never smokers. However, we observed elevated bladder cancer risk among male never smokers: compared with nondrinkers, 0.1-0.9, 1-1.9, 2-2.9 and ≥3 cups/day of decaffeinated coffee intake were associated with HRs of 1.30 (95% CI 1.01-1.68), 1.42 (95% CI 1.00-2.03), 1.43 (95% CI 0.91-2.23), and 1.79 (95% CI 0.92-3.50), respectively, with borderline significant linear trends (Ptrend = 0.06). This positive association remained robust in various sensitivity analyses and became even stronger with an 8-year lag. No association between decaffeinated coffee and bladder cancer was observed among women (Psex-heterogeneity = 0.03). CONCLUSIONS: Higher decaffeinated coffee intake was not associated with total cancer risk. However, the observed significant higher risk of bladder cancer in men warrants further studies.
引用
- Zhang Y, Ma C, Zhao L, et al. Decaffeinated coffee consumption and risk of total and site-specific cancer. Ann Oncol. 2025. PMID: 40180122. doi:10.1016/j.annonc.2025.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。